美国心脏协会/美国心脏病学会/心律学会心房颤动管理指南的证据质量
该研究分析了2001、2006、2011和2014年AHA/ACC/HRS心房颤动指南共437条推荐,评估推荐类别和证据等级分布及变化。2014版指南中仅8.8%推荐由A级证据支持,51.3%由C级证据支持;A级证据使用自2001年以来未增加。
要点
- 2014版指南113条推荐中,A级证据仅10条(8.8%),C级证据58条(51.3%)。
- I类推荐中59.2%(29/49)由C级证据支持,仅12.2%(6/49)由A级证据支持。
- 2001至2014年A级证据使用无显著变化(8.4% vs 8.8%,P=.92)。
核心结论
- AHA/ACC/HRS房颤指南部分证据质量随时间有所改善,但A级证据使用仍低且自2001年以来未增加,作者认为需要针对房颤临床管理开展聚焦的实用性随机研究。
研究设计与样本
- 研究提取2001、2006、2011和2014年AHA/ACC/HRS房颤指南的数据,共纳入437条推荐,分析各版指南推荐类别(I、II、III)和证据等级(A、B、C)的分布及2001与2014版间的变化。
主要发现
- 2001至2014年房颤推荐总数从95条增至113条。
- B级证据使用从30.5%增至39.8%(P=.17),C级证据使用从60.0%降至51.3%(P=.21),A级证据使用从8.4%至8.8%(P=.92),均未达统计学显著。
- 2014版指南中,I类推荐49/113条(43.4%),IIa/IIb类推荐49/113条(43.4%),III类推荐15/113条(13.3%)。
- 2014版指南I类推荐中,C级证据支持29/49条(59.2%),A级证据支持6/49条(12.2%)。
- 2014版指南中无心率控制类推荐由A级证据支持。
关键数值与推荐
- 2014版指南113条推荐中,A级证据10条(8.8%),C级证据58条(51.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The joint American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) guidelines on the management of atrial fibrillation (AF) are used extensively to guide patient care. OBJECTIVE: To describe the evidence base and changes over time in the AHA/ACC/HRS guidelines on AF with respect to the distribution of recommendations across classes of recommendations and levels of evidence. DATA SOURCES: Data from the AHA/ACC/HRS guidelines on AF from 2001, 2006, 2011, and 2014 were abstracted. A total of 437 recommendations were included. DATA EXTRACTION AND SYNTHESIS: The number of recommendations and distribution of classes of recommendation (I, II, and III) and levels of evidence (A, B, and C) were determined for each guideline edition. Changes in recommendation class and level of evidence were analyzed using the 2001 and 2014 guidelines. RESULTS: From 2001 to 2014, the total number of AF recommendations increased from 95 to 113. Numerically, there was a nonsignificant increase in the use of level of evidence B (30.5% to 39.8%; P = .17) and a nonsignificant decrease in the use of level of evidence C (60.0% to 51.3%; P = .21), with limited changes in the use of level A evidence (8.4% to 8.8%; P = .92). In the 2014 guideline document, 10 of 113 (8.8%) recommendations were supported by level of evidence A, whereas 58 of 113 (51.3%) were supported by level of evidence C. Most recommendations were equally split among class I (49/113; 43.4%) and class IIa/IIb (49/113; 43.4%), with the minority (15/113; 13.3%) assigned as class III. Most class I recommendations were supported by level of evidence C (29/49; 59.2%), whereas only 6 of 49 (12.2%) were supported by level of evidence A. No rate control category recommendations were supported by level of evidence A. CONCLUSIONS AND RELEVANCE: Some aspects of the quality of evidence underlying AHA/ACC/HRS AF guidelines have improved over time. However, the use of level of evidence A remains low and has not increased since 2001. These findings highlight the need for focused and pragmatic randomized studies on the clinical management of AF.
引用
- Barnett AS, Lewis WR, Field ME, et al. Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiol. 2017. PMID: 28002833. doi:10.1001/jamacardio.2016.4936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。